SCHEMBL4795455

SCHEMBL4795455

CCOC(=O)c1n[nH]c2c[c]ccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.68
POLB P06746 1/20 0.55
NPC1 O15118 6/20 0.47
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
RAB9A P51151 5/20 0.47
HTT P42858 3/20 0.47
LMNA P02545 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
STAT3 P40763 1/20 0.46
HIF1A Q16665 1/20 0.46
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HSD17B10 Q99714 3/20 0.43
TP53 P04637 2/20 0.43
USP2 O75604 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4794655 0.90 KDM4E (0.66) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL29709972 0.81 KDM4E (1.00) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL959364 0.81 KDM4E (1.00) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL2013950 0.79 KDM4E (0.41) KDM4ENPC1MAPTSMN1; SMN2RAB9A
SCHEMBL12090413 0.78 KDM4E (0.69) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL13337410 0.77 KDM4E (0.68) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL177200 0.77 KDM4E (0.68) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL14166062 0.77 KDM4E (0.68) KDM4EPOLBNPC1MAPTSMN1; SMN2
SCHEMBL20505137 0.77 PRKAG1 (0.42) KDM4ESTAT3HIF1A
SCHEMBL20895120 0.76 KDM4E (0.66) KDM4EPOLBNPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A KDM4E 2328/4885POLB 758/4885NPC1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.